As of Nov 19, 2026, 1 of 1 active firms rate HBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HBIO EPS & revenue forecast
EPS · NEXT QUARTER
$0.11
Range $0.11 – $0.11 · 1 analysts
Next period, 1 analysts expect Harvard Bioscience Inc to earn $0.11 a share (range $0.11 – $0.11), versus — a year earlier. Full-year consensus is $-0.34, growing to $0.53 the year after.
REVENUE · NEXT QUARTER
$22.6M
Range $21.8M – $23.5M · 1 analysts · +9% YoY
Revenue is expected to reach $22.6M (range $21.8M – $23.5M), +9.1% year-over-year. Full-year consensus is $90.1M, rising to $94.8M next year.
Top analysts covering Harvard Bioscience Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HBIO.
#1
Paul Knight
Keybanc · Rank #394
Neutral
No targeton HBIO
Overall win rate
39%
+ Follow
#2
Bruce Jackson
Benchmark · Rank #487
Buy
$7.50-16.9% to target
Overall win rate
36%
+ Follow
HBIO stock forecast FAQ
What is HBIO's average 12-month price target?+
The 1 active firms with a live target average $7.50 for Harvard Bioscience Inc over the next 12 months, ranging from a $7.50 high to a $7.50 low, as of Nov 19, 2026.
Is HBIO stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover HBIO?+
1 active firms have a recognized rating on Harvard Bioscience Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HBIO?+
Among analysts who currently cover HBIO, Paul Knight of Keybanc has the strongest overall Quantellect track record (Rank #394). Their current call is Neutral.
What is Harvard Bioscience Inc's projected EPS for next quarter?+
The consensus estimate is $0.11 per share (range $0.11 – $0.11) across 1 analysts. Full-year EPS is projected at $-0.34, rising to $0.53 the following year.
How much revenue is Harvard Bioscience Inc expected to report next quarter?+
Consensus revenue is $22.6M (range $21.8M – $23.5M). Full-year revenue is projected at $90.1M, growing to $94.8M next year.
Have analysts been upgrading or downgrading HBIO lately?+
As of Nov 19, 2026, 1 of 1 active firms rate HBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.